Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 225

Sort by

Sort Order Select

Journal Articles

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Kitsada Wudhikarn, Jessica R. Flynn, Isabelle Rivière, Mithat Gönen, Xiuyan Wang, Brigitte Senechal, Kevin J. Curran, Mikhail Roshal, Peter G. Maslak, Mark B. Geyer, Elizabeth F. Halton, Claudia Diamonte, Marco L. Davila, Michel Sadelain, Renier J. Brentjens, Jae H. Park

Blood (2021) 138 (7): 531–543.

https://doi.org/10.1182/blood.2020009515

Published: 2021

Includes: Supplemental data

Journal Articles

DARTs point the way forward in AML

Saar Gill

Blood (2021) 137 (6): 720–721.

https://doi.org/10.1182/blood.2020009020

Published: 2021

Journal Articles

Blinatumomab for infant acute lymphoblastic leukemia

Katherine Clesham, Vasudha Rao, Jack Bartram, Philip Ancliff, Sara Ghorashian, David O’Connor, Vesna Pavasovic, Anupama Rao, Sujith Samarasinghe, Michelle Cummins, Andrea Malone, Katharine Patrick, Denise Bonney, Beki James, Brenda Gibson, Ajay Vora

Blood (2020) 135 (17): 1501–1504.

https://doi.org/10.1182/blood.2019004008

Published: 2020

Journal Articles

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Ibrahim Aldoss, Stephen J. Forman

Blood (2020) 135 (11): 804–813.

https://doi.org/10.1182/blood.2019002132

Published: 2020

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_2): LBA-1.

https://doi.org/10.1182/blood-2019-132435

Published: 2019

Journal Articles

Blinatumomab-Induced T Cell Activation at Single Cell Transcriptome Resolution

Hong Yin, MD PhD, Yi Huo, PhD, Zhen Sheng, PhD, Chi-Ming Li, PhD, Daniel C Ellwanger, PhD, Daniel Lu, PhD, Oliver Homann, PhD, Songli Wang, MD PhD, Ruibao Ren, MD PhD

Blood (2019) 134 (Supplement_1): 3886.

https://doi.org/10.1182/blood-2019-124636

Published: 2019

Journal Articles

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Amber C. King, PharmD, BCOP, Jae H. Park, MD, Mark B. Geyer, MD

Blood (2019) 134 (Supplement_1): 3887.

https://doi.org/10.1182/blood-2019-128506

Published: 2019

Journal Articles

Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss

Xiaochuan Yang, Amber C. King, PharmD, BCOP, Charlene C. Kabel, PharmD, Christopher J. Forlenza, MD, Jae H. Park, MD, Mark B. Geyer, MD

Blood (2019) 134 (Supplement_1): 3888.

https://doi.org/10.1182/blood-2019-125165

Published: 2019

Journal Articles

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Erica Brivio, MD, Raoull Hoogendijk, MSc, Christophe Chantrain, MD PhD, Fanny Rialland, MD, Audrey Contet, Sarah Elitzur, MD, Luciano Dalla-Pozza, MBBS FRACP, Krisztian Kallay, MD, Chi Kong Li, MBBS,MD, Motohiro Kato, MD PhD, Inna V Markova, Dr., Kjeld Schmiegelow, Professor MD DMSc., Nicole Bodmer, Rob Pieters, MDPhDMSc, Christian Michel Zwaan, MD PhD

Blood (2019) 134 (Supplement_1): 3890.

https://doi.org/10.1182/blood-2019-126472

Published: 2019

Journal Articles

Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity

Anilkumar Gopalakrishnapillai, PhD, Colin Correnti, PhD, Anne Kisielewski, BS, Allison Kaeding, MD, Soheil Meshinchi, MD PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 3925.

https://doi.org/10.1182/blood-2019-130941

Published: 2019

Journal Articles

A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies

Hamid Bolouri, PhD, Benjamin K. Johnson, PhD, Rhonda E. Ries, MA, Laura Pardo, Tiffany A. Hylkema, BS, Wanding Zhou, PhD, Jenny L. Smith, MSc, MD, Amanda R. Leonti, MS, Allison Kaeding, MD, Michael R. Loken, PhD, Jason E. Farrar, MD, Soheil Meshinchi, MD PhD, Timothy Junius Triche, Jr., PhD

Blood (2019) 134 (Supplement_1): 3768.

https://doi.org/10.1182/blood-2019-123487

Published: 2019

Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Blood (2019) 134 (Supplement_1): 3806.

https://doi.org/10.1182/blood-2019-129018

Published: 2019

Journal Articles

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab

Blood (2019) 134 (Supplement_1): 3809.

https://doi.org/10.1182/blood-2019-125466

Published: 2019

Journal Articles

Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience

Blood (2019) 134 (Supplement_1): 3876.

https://doi.org/10.1182/blood-2019-131123

Published: 2019

Journal Articles

Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Guillaume Richard-Carpentier, MD, Hagop M. Kantarjian, MD, Nicholas J. Short, MD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Heather M Schroeder, Guillermo Garcia-Manero, MD, Guillermo Montalban Bravo, MD, Jorge E. Cortes, MD, Monica Kwari, BSN, Christopher Loiselle, BS, Rebecca Garris, MSc, Nicole Volter, RDC, Nitin Jain, MD, Marina Y Konopleva, MD PhD, Koichi Takahashi, MD, Koji Sasaki, MD, William G. Wierda, MD PhD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 3807.

https://doi.org/10.1182/blood-2019-129657

Published: 2019

Journal Articles

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

James K McCloskey, MD, Joelle Gagnon, NP, Tara McCabe, FNP-C, MSN, RN, BSN, Jocelyn Charlon, MS, AGPCNP-BC, Shuqi Wang, MSc, Ruzong Fan, Stuart L. Goldberg, MD, Jamie Koprivnikar, MD

Blood (2019) 134 (Supplement_1): 3812.

https://doi.org/10.1182/blood-2019-131838

Published: 2019

Journal Articles

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Marc Schwartz, MD, Lloyd E. Damon, MD, Deepa Jeyakumar, MD, Caitlin L. Costello, MD, Dimitrios Tzachanis, MD PhD, Gary J. Schiller, MD, Jesika Reiner, MPH, Matthew J. Wieduwilt, MD PhD

Blood (2019) 134 (Supplement_1): 3880.

https://doi.org/10.1182/blood-2019-131061

Published: 2019

Journal Articles

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Deborah A. Katz, MD, Michael P. Chu, Kevin A. David, MD, Catherine Thieblemont, MD PhD, Nicholas J. Morley, Sharif S. Khan, Yuqi Chen, James Kalabus, Joan Morris, Abraham Anderson, Ariel A. Avilion, Eva González-Barca, MD PhD

Blood (2019) 134 (Supplement_1): 4077.

https://doi.org/10.1182/blood-2019-121708

Published: 2019

Journal Articles

Predictors of Efficacy for Blinatumomab in BCP-ALL Patients: Non-Responders Show Impaired CD19-BiTE®-Mediated Cytotoxicity in Vitro

Veit Bücklein, MD, Michaela Scheurer, Bettina Brauchle, MSc, Roman Kischel, MD, Michael von Bergwelt, Karsten Spiekermann, MD, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 2632.

https://doi.org/10.1182/blood-2019-129057

Published: 2019

Journal Articles

Comorbidities Reduce Response to Induction Treatment and Survival in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia

Ilaria Tanasi, Veronica Tagliaferri, Cristina Tecchio, Fiorenza Aprili, Giovanna De Matteis, Giovanni Pizzolo, Mauro Krampera, Massimiliano Bonifacio, MD

Blood (2019) 134 (Supplement_1): 2587.

https://doi.org/10.1182/blood-2019-130160

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

DARTs point the way forward in AML

Blinatumomab for infant acute lymphoblastic leukemia

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Blinatumomab-Induced T Cell Activation at Single Cell Transcriptome Resolution

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity

A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab

Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience

Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Predictors of Efficacy for Blinatumomab in BCP-ALL Patients: Non-Responders Show Impaired CD19-BiTE®-Mediated Cytotoxicity in Vitro

Comorbidities Reduce Response to Induction Treatment and Survival in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only